Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors

被引：22

作者：

De Giorgi, Ugo ^{[1
]}

Casadei, Chiara ^{[1
]}

Bergamini, Alice ^{[2
]}

Attademo, Laura ^{[3
]}

Cormio, Gennaro ^{[4
]}

Lorusso, Domenica ^{[5
]}

Pignata, Sandro ^{[3
]}

Mangili, Giorgia ^{[2
]}

机构：

[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol & Hematol, I-47014 Meldola, Italy

[2] Ist Sci San Raffaele, Dept Obstet & Gynaecol, I-20132 Milan, Italy

[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, I-80138 Naples, Italy

[4] IRCCS Ist Oncol Giovanni Paolo II, Gynecol Oncol Unit, I-70124 Bari, Italy

[5] Fdn Policlin Univ Agostino Gemelli, Dept Woman Child Hlth & Publ Hlth, Gynecol Oncol Unit, IRCCS, I-00168 Rome, Italy

来源：

CANCERS | 2019年 / 11卷 / 10期

关键词：

female patients; germ cell tumors; ovarian germ cell tumors; salvage therapy; refractory; high-dose chemotherapy; HIGH-DOSE CHEMOTHERAPY; PHASE-II TRIAL; SALVAGE CHEMOTHERAPY; TESTICULAR CANCER; CYTOPLASMIC P21; EXPRESSION; IFOSFAMIDE; PACLITAXEL; DIAGNOSIS; BLEOMYCIN;

D O I：

10.3390/cancers11101584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. The treatment of cisplatin-resistant disease is challenging and prognosis remains poor. There are limited data on the efficacy of specific chemotherapeutic regimens, high-dose chemotherapy with autologous progenitor cell support and targeted therapies. The inclusion of patients in clinical trials is strongly recommended, especially in clinical trials on the most frequent male germ cell tumors, to offer wider therapeutic opportunities. Here, we provide an overview of current and potential new treatment options including combination chemotherapy, high-dose chemotherapy and molecular targeted therapies, for patients with cisplatin-resistant ovarian germ cell tumors.

引用

页数：14

共 90 条

[1] Cisplatin Induces Resistance by Triggering Differentiation of Testicular Embryonal Carcinoma Cells [J].

Abada, Paolo B. ;

Howell, Stephen B. .

PLOS ONE, 2014, 9 (01)

[2] Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 [J].

Adra, N. ;

Einhorn, L. H. ;

Althouse, S. K. ;

Ammakkanavar, N. R. ;

Musapatika, D. ;

Albany, C. ;

Vaughn, D. ;

Hanna, N. H. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :209-214

[3] Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine [J].

Albany, Costantine ;

Hever-Jardine, Mary P. ;

von Herrmann, Katherine M. ;

Yim, Christina Y. ;

Tam, Janice ;

Warzecha, Joshua M. ;

Shin, Leah ;

Bock, Sarah E. ;

Curran, Brian S. ;

Chaudhry, Aneeq S. ;

Kim, Fred ;

Sandusky, George E. ;

Taverna, Pietro ;

Freemantle, Sarah J. ;

Christensen, Brock C. ;

Einhorn, Lawrence H. ;

Spinella, Michael J. .

ONCOTARGET, 2017, 8 (02) :2949-2959

[4] Surgery is an essential part of salvage treatment in refractory germ cell tumors [J].

Albers, Peter .

EUROPEAN UROLOGY, 2006, 50 (05) :893-894

[5] High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors [J].

Ammakkanavar, Natraj Reddy ;

Matei, Daniela ;

Abonour, Rafat ;

Einhorn, Lawrence H. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :226-U148

[6]

ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35

[7] Teratocarcinomas and human embryology: Pluripotent human EC cell lines [J].

Andrews, PW .

APMIS, 1998, 106 (01) :158-167

[8] ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].

BARRY, MA ;

BEHNKE, CA ;

EASTMAN, A .

BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362

[9] Deregulation of the RB pathway in human testicular germ cell tumours [J].

Bartkova, J ;

Lukas, C ;

Sorensen, CS ;

Rajpert-De Meyts, E ;

Skakkebæk, NE ;

Lukas, J ;

Bartek, J .

JOURNAL OF PATHOLOGY, 2003, 200 (02) :149-156

[10] Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer [J].

Beyer, J. ;

Albers, P. ;

Altena, R. ;

Aparicio, J. ;

Bokemeyer, C. ;

Busch, J. ;

Cathomas, R. ;

Cavallin-Stahl, E. ;

Clarke, N. W. ;

Classen, J. ;

Cohn-Cedermark, G. ;

Dahl, A. A. ;

Daugaard, G. ;

De Giorgi, U. ;

De Santis, M. ;

De Wit, M. ;

De Wit, R. ;

Dieckmann, K. P. ;

Fenner, M. ;

Fizazi, K. ;

Flechon, A. ;

Fossa, S. D. ;

Germa Lluch, J. R. ;

Gietema, J. A. ;

Gillessen, S. ;

Giwercman, A. ;

Hartmann, J. T. ;

Heidenreich, A. ;

Hentrich, M. ;

Honecker, F. ;

Horwich, A. ;

Huddart, R. A. ;

Kliesch, S. ;

Kollmannsberger, C. ;

Krege, S. ;

Laguna, M. P. ;

Looijenga, L. H. J. ;

Lorch, A. ;

Lotz, J. P. ;

Mayer, F. ;

Necchi, A. ;

Nicolai, N. ;

Nuver, J. ;

Oechsle, K. ;

Oldenburg, J. ;

Oosterhuis, J. W. ;

Powles, T. ;

Rajpert-De Meyts, E. ;

Rick, O. ;

Rosti, G. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :878-888

← 1 2 3 4 5 6 7 8 9 →